NCT07580664

Brief Summary

The goal of this clinical trial is to estimate the cumulative reoperation rate at upper adjacent segment level in patients treated with BDyn dynamix stabilization for lumbar degenerative disc diseases over long-term follow-up. Patients will provide baseline socio-demographic and surgical data, complete patient-reported outcome measures (ODI, pain NRS, satisfaction), undergo imaging assessments (dynamic X-rays, EOS, MRI), and participate in safety evaluations including adverse event monitoring throughout follow-up.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
10mo left

Started Apr 2026

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress14%
Apr 2026Apr 2027

Study Start

First participant enrolled

April 1, 2026

Completed
27 days until next milestone

First Submitted

Initial submission to the registry

April 28, 2026

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 12, 2026

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2027

Last Updated

May 12, 2026

Status Verified

May 1, 2026

Enrollment Period

1 year

First QC Date

April 28, 2026

Last Update Submit

May 5, 2026

Conditions

Keywords

BDynDynamic stabilizationLumbar stabilization

Outcome Measures

Primary Outcomes (1)

  • Reoperation rate at the upper adjacent segment

    Cumulative reoperation rate at the upper adjacent segment will be defined as the occurrence of reoperation at this level over long-term postoperative follow-up (≥4 years)

    Through study completion, an average of 10 year

Secondary Outcomes (12)

  • Reoperation rate at the instrumented segment

    Through study completion, an average of 10 year

  • Describe upper adjacent segment integrity

    Through study completion, an average of 10 year

  • Describe segmental range of motion (ROM) of the stabilized segment, the upper and lower adjacent segment

    Through study completion, an average of 10 year

  • Describe disc height of the stabilized segment, the upper and lower adjacent segment

    Through study completion, an average of 10 year

  • Describe sagittal balance

    Through study completion, an average of 10 year

  • +7 more secondary outcomes

Study Arms (1)

Patients treated with BDyn dynamic stabilization

EXPERIMENTAL

All enrolled patients undergo lumbar dynamic stabilization using the BDyn device. Clinical, radiological, and patient-reported outcomes are collected during long-term follow-up.

Device: Dynamic Lumbar Stabilization Device

Interventions

BDyn is intended for spine surgery with a posterio approach. The sterile spinal dynamic posterior stabilization devices BDyn is intended to restore the stabilization of the spine segment from T10 to S1 by preserving the anatomical lordosis and the deadening of the intervertebral joint.

Also known as: BDyn, BDyn device, BDyn Cousin Biotech, B-Dyn
Patients treated with BDyn dynamic stabilization

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient, male or female, aged ≥ 18 years old
  • Patient treated with BDyn device until end of December 2021, with between one and four fused level(s) maximum for the following indications: Degenerative intervertebral disc disease and/or articular facets confirmed by further examinations, Spinal canal stenosis, Degenerative spondylolisthesis grade 1, Segmental instability
  • Patient who signed the informed consent form
  • Patient affiliated with a social security scheme

You may not qualify if:

  • Patients who are unable to provide informed consent due to cognitive impairment, language barrier, or any other condition that limits their ability to understand the nature, objectives, or potential risks of the study
  • Patient that is pregnant or breastfeeding;
  • Patient with protected status under articles L1121-6, LL121-8 and L1122-2 of the French Public Health Code;
  • Patient who cannot comply with the protocol requirements based on the investigator's judgment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Intervertebral Disc Degeneration

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 28, 2026

First Posted

May 12, 2026

Study Start

April 1, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

April 1, 2027

Last Updated

May 12, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will not share